Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biovet JSCLTS:0III Earnings Yield (Joel Greenblatt) % is 14.43% as of Dec. 2016, which is 6% above its 10-year median of 13.60. The stock has 1 warning sign investors should review.
Biovet JSC's Enterprise Value for the quarter that ended in Dec. 2016 was лв0.00 Mil.
Biovet JSC's EBIT for the trailing twelve months (TTM) ended in Dec. 2016 was лв19.74 Mil. Biovet JSC's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2016 was 14.43%.
The historical rank and industry rank for Biovet JSC's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
LTS:0III'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.7 Med: 13.6 Max: 18.4
Current: 14.86
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Biovet JSC was 18.40%. The lowest was 3.70%. And the median was 13.60%.
LTS:0III's Earnings Yield (Joel Greenblatt) % is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.99
vs LTS:0III: 14.86
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Biovet JSC's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2016 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Biovet JSC Earnings Yield (Joel Greenblatt) % Related Terms
Biovet JSC Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Biovet JSC's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biovet JSC's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biovet JSC Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biovet JSC's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Biovet JSC's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Biovet JSCs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2016 is calculated as
Biovet JSC's EBIT for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was лв19.74 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 14.43% mean?
Biovet JSC (LTS:0III) has a Earnings Yield (Joel Greenblatt) % of 14.43% as of Dec. 2016. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Biovet JSC and its competitors. This is near median its historical median of 13.60. Over the past decade, Biovet JSC's Earnings Yield (Joel Greenblatt) % has ranged from 3.70 to 18.40.
Is Biovet JSC's Earnings Yield (Joel Greenblatt) % too high?
Biovet JSC's current Earnings Yield (Joel Greenblatt) % of 14.43% is near median its 10-year median of 13.60. Over the past 10 years, this metric has ranged from a low of 3.70 to a high of 18.40. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 2.99. Biovet JSC's value of 14.43% is 382.6% above this industry median.
How does Biovet JSC's Earnings Yield (Joel Greenblatt) % compare to ADMP and AGRX?
Biovet JSC's Earnings Yield (Joel Greenblatt) % of 14.43% can be compared against companies in the Drug Manufacturers industry. The industry median Earnings Yield (Joel Greenblatt) % is 2.99. Biovet JSC's value of 14.43% is 382.6% above this benchmark. Historically, Biovet JSC's own Earnings Yield (Joel Greenblatt) % has ranged from 3.70 to 18.40 over the past decade. While the company's 10-year median is 13.60 vs. the industry median of 2.99, Biovet JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 2.99, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biovet JSC's current Earnings Yield (Joel Greenblatt) % of 14.43% is 382.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Biovet JSC and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biovet JSC's current Earnings Yield (Joel Greenblatt) % is 14.43%, which is near median its own 10-year median of 13.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biovet JSC stock overvalued right now?
Biovet JSC (LTS:0III) has a current Earnings Yield (Joel Greenblatt) % of 14.43%. The current Earnings Yield (Joel Greenblatt) % is 14.43%, which is near median its 10-year median of 13.60 and 382.6% above the Drug Manufacturers industry median of 2.99. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Biovet JSC (LTS:0III), the current Earnings Yield (Joel Greenblatt) % is 14.43% as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biovet JSC manufactures & markets medicated and nutritional feed additives, enzymes, bulk active substances & pharmaceuticals for animal productivity & health. It offers intermediates, active ingredients and medicines for human pharmaceutical industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0III has been successfully added to your 
